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PERSPECTIVE
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Abstract
Introduction: We propose a minimum data set framework for the acquisition and
analysis of retinal images for the development of retinal Alzheimer’s disease (AD)
biomarkers. Our goal is to describe methodology that will increase concordance across
laboratories, so that the broader research community is able to cross-validate findings
in parallel, accumulate large databases with normative data across the cognitive aging
spectrum, and progress the application of this technology from the discovery stage to
the validation stage in the search for sensitive and specific retinal biomarkers in AD.
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Methods: The proposed minimum data set framework is based on the Atlas of Retinal
Imaging Study (ARIAS), an ongoing, longitudinal, multi-site observational cohort study.
However, the ARIAS protocol has been edited and refined with the expertise of all coauthors, representing 16 institutions, and research groups from three countries, as a
first step to address a pressing need identified by experts in neuroscience, neurology,
optometry, and ophthalmology at the Retinal Imaging in Alzheimer’s Disease (RIAD)
conference, convened by the Alzheimer’s Association and held in Washington, DC, in
May 2019.
Results: Our framework delineates specific imaging protocols and methods of analysis
for imaging structural changes in retinal neuronal layers, with optional add-on procedures of fundus autofluorescence to examine beta-amyloid accumulation and optical
coherence tomography angiography to examine AD-related changes in the retinal vasculature.
Discussion: This minimum data set represents a first step toward the standardization
of retinal imaging data acquisition and analysis in cognitive aging and AD. A standardized approach is essential to move from discovery to validation, and to examine which
retinal AD biomarkers may be more sensitive and specific for the different stages of
the disease severity spectrum. This approach has worked for other biomarkers in the
AD field, such as magnetic resonance imaging; amyloid positron emission tomography;
and, more recently, blood proteomics. Potential context of use for retinal AD biomarkers is discussed.

1

INTRODUCTION

most critical of these is the need for at least initial agreement on
basic standards for data acquisition and analyses, to allow increased

In the current volume of Alzheimer’s & Dementia, Snyder et al.1

opportunities for data sharing across research groups. This will

present the proceedings of an international conference hosted

allow researchers in the field to compare imaging data across study

by the Alzheimer’s Association in Washington, DC, in May 2019,

cohorts, and eventually would lead to the creation of a widely available

which brought together experts in Alzheimer’s disease (AD) with

comparative reference database, along the lines of the Alzheimer’s

leading clinicians and researchers in optometry, ophthalmology, and

Disease Neuroimaging Initiative (ADNI3–5 ) and the Australian Imaging

neuro-ophthalmology for a 2-day summit entitled “Retinal Imaging

Biomarkers and Lifestyle Study (AIBL6 ) among other large-scale

in Alzheimer’s Disease.” The focus of this meeting was to promote

longitudinal observational trials. These landmark studies have led to

collaborative efforts between AD researchers and retinal specialists in

massive improvements in how we acquire and interpret neuroimaging

pursuit of the discovery and validation of retinal AD risk biomarkers.

and biofluids markers for the disease.

Because the retina is an extension of the central nervous system, the

Here, we propose a framework for a “minimum data set” for use

development and validation of such biomarkers would allow for a

in retinal imaging and signal processing across laboratories, based on

non-invasive, inexpensive, and relatively rapid method for the routine

our collective experience and an exhaustive decision-making process

screening of AD risk and progression in large populations of older

that led to the design of a current multi-site longitudinal observational

adults.2 Given the lack of preventative or disease-modifying therapies

trial, led by two of us (P.J.S. and S.S.), the Atlas of Retinal Imaging in

for AD, and the fact that the majority of adults over the age of 40 see

Alzheimer’s Study (ARIAS) that launched recruitment of participants

an eye care professional intermittently for preventive eye health and

in January 2020. We began with this protocol, and sought input

vision examinations, correction of refractive error (including pres-

from international experts in this area (all co-authors) to reach a

byopia), and/or ongoing monitoring of ocular abnormalities, retinal

consensus on a recommended minimum data set. Our aim is to propose

screening could serve as a cost-effective, widely accessible method

reproducible methods that can be used across laboratories to aggre-

to address a major public health need. This first-ever international

gate data, cross-validate findings, and accelerate the development

conference on retinal imaging in AD identified several key action items

of sensitive and specific retinal biomarkers for the early detection

or next steps to move retinal AD biomarker research from its current

of Alzheimer’s pathologic change. Although we are well aware that

position in the discovery phase to the validation phase. Perhaps the

the field is not yet ready to reach a consensus on methods, and that
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site-specific differences in the actual optical coherence tomography
(OCT) measurements of retinal markers exist due to proprietary

RESEARCH IN CONTEXT

differences in manufacturing technologies and processing software.
While this cannot be solved with the suggestion of this framework,
we are hopeful that publishing this methodology serves as a first step
toward finding common approaches that will improve our ability to
harmonize data and to cross-validate results across research centers
dedicated to the discovery and validation of retinal biomarkers of AD.

1. Systematic review: The Alzheimer’s Association, in partnership with this journal, hosted a first-ever international
think-tank meeting on the topic of retinal imaging in
Alzheimer’s disease (AD) in May 2019, attended by 90
experts from nine countries 1 One of the key recommendations from the conference was to develop consensus on
an initial “minimum data set approach” for future studies,

1.1
A proposed framework for a minimum data
set in AD biomarker research: spectral domain
optical coherence tomography (SD-OCT) image
collection and processing

to allow enhanced potential to compare, and/or to coalesce, data collected across multiple laboratories and clinics.
2. Interpretation: This initial attempt at outlining a minimum data set, retinal imaging studies in AD, is based on

We propose a framework that encompasses structural SD-OCT imaging of the optic disc and the macula, to capture volume and thickness changes of the peripapillary retinal nerve fiber layer (pRNFL),
macular retinal nerve fiber layer (mRNFL), ganglion cell layer (GCL),
inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform
layer (OPL), outer nuclear layer (ONL), inner and outer photoreceptor segments (IS and OS), and the retinal pigment epithelium (RPE).
Because structural changes in the retina in AD have been robustly supported by the growing literature on this topic over the past decade2
and all SD-OCT devices support structural retinal imaging, we propose this as a core image acquisition and processing framework. We
also propose some additional image acquisition and processing techniques: fundus autofluorescence imaging to examine protein changes

a large trial that is currently in progress; but that protocol has now been edited and refined with the expertise of
all co-authors, representing 16 institutions, and research
groups from three countries.
3. Future directions: We hope that this set of recommendations will be considered by, improved, further
refined, and adopted by additional research groups and
by the new Professional Interest Area (PIA) group of the
Alzheimer’s Association International Society to Advance
Alzheimer’s Research and Treatment (ISTAART) that has
just recently been launched as another major recommendation from the "Retinal Imaging in AD" conference referenced above.1

and OCT-angiography (OCT-A) of the retinal microvasculature.
As noted above, these methods are being used in the ARIAS trial
that is following a large cohort (N = 330) longitudinally for 5 years at
three sites in Florida and Rhode Island (NCT# = 03862222). In addi-

within the same company and SD-OCT system, periodic improve-

tion to an extensive retinal imaging protocol, ARIAS will also collect

ments in their signal processing software packages result in subtle

genetic, cognitive, sleep, gait, functional, pupillometry, contrast sensi-

differences in segmentation algorithms, possibly creating an additional

tivity, brain imaging (amyloid positron emission tomography [PET] and

source of instrumental variability between labs and between patient

magnetic resonance imaging [MRI], for a subset of participants), and

visits. It is beyond the scope of this article to recommend how such

blood proteomics data. After completion of data collection and initial

sources of instrumental error should be addressed when coalescing

analyses, we plan to make this database publicly available as a refer-

data across labs, or even within the same center over time. However,

ence for other researchers, patterned after the data-sharing approach

we firmly believe that potential between-center main effect differ-

pioneered by ADNI.

ences for vendor/imaging systems need to be thoroughly explored,
with multiple research groups working cooperatively, to both collect
and then share data sets that can be at least partially merged for

1.2
Instrumental variability across centers
and research groups

statistical analyses, or at least used to derive mathematical equations
for conversions between instruments, as has been done previously for
diabetic retinopathy.7

Multiple instrument manufacturers including, but not limited to, Zeiss,

We are of the opinion that appropriate adjustments will be

Heidelberg Engineering, Topcon, and Optovue, are all producing very

identified to allow data obtained on one manufacturer’s system to

high-quality SD-OCT imaging systems that are in wide clinical and

be compared reliably to the same type of data obtained on other

research use worldwide. Although each of these systems produce very

systems–and this work stream would clearly advance more rapidly

similar-looking and high-quality images, technical specifications do

with the cooperation of the manufacturers themselves. In the protocol

vary across these devices that lead to important differences in optics,

we describe below, we have chosen to use the same Heidelberg

in-plane resolution, the ability to map point-to-point over successive

Engineering, Inc. (Heidelberg, Germany) SPECTRALIS 2 OCT system

exams, and many other instrumental differences. Moreover, even

at all three clinical sites. Hence, many of the specifications described
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below are specific to this particular vendor. We offer this as an exam-

other (or, in the presence of substantial bilateral ocular disease, would

ple, and would encourage centers relying on imaging systems from

exclude a participant from the study altogether). In at least some cases,

other vendors to match the protocol below to accelerate the work of

ophthalmic evaluation is necessary to evaluate the disease severity

understanding these potential instrument differences.

and to develop reproducible inclusion and exclusion criteria.

We also acknowledge that several investigators in academia and

For structural OCT imaging, to avoid inter- and intra-subject thick-

industry are developing novel experimental technologies and engineer-

ness measurement biases due to axial length,11 we correct using a mod-

ing advances that may supersede some or all of the imaging technolo-

ified Littman’s formula, which is currently in use by several investiga-

gies that we currently rely on, in terms of sensitivity and specificity for

tors in this field.12 For sites unable to measure axial length, participants

AD risk biomarkers (cf. Liu et al.8 Yap et al.,9 and Braaf et al.10 ). Here, we

with <or >5.0 diopters native spherical equivalent should be excluded.

focus on current widely available clinical tools that can be deployed by

Additionally, although regulations surrounding storage of demographic

point-of-care clinicians for validation of retinal biomarkers in the near-

information vary regionally, nationally, and internationally, we recom-

term future.

mend collecting the following demographic variables as a minimum:
age, years of education, race, sex. All of these factors can affect retinal
morphology and/or cognition in AD, and may be required as covariates

1.3

Quality control and quality assurance

in analyses examining between- or within-subject comparisons.

The veracity of biomarker research, of any type, is utterly dependent on
study subject selection and ensuring consistent assurance and quality

1.4.1

Structural SD-OCT imaging at optic disc

control (QA/QC), across clinical sites, across technicians and research
staff who are collecting data, and across time for within-subjects

For research groups relying on the imaging system produced by Hei-

longitudinal studies. This important set of issues also lies beyond the

delberg Engineering, the SPECTRALIS HRA + OCT glaucoma imaging

scope of this article, but the ability to trust any of the retinal imaging

module should be used, centered on the optic disc, consisting of three

biomarkers that we describe below is nonetheless dependent on study

concentric circles of diameters 3.5, 4.1, and 4.7 mm. This imaging proto-

designs that effectively ensure proper QA/QC of the data obtained.

col should be completed in high-speed (HS) mode, with 27 B-scans for
each of the three concentric circles and 30 frames averaged per each
B-scan location. Segmentation is completed automatically with HEYEX

1.4

Structural imaging protocol

software. For centers relying on systems produced by other companies,
we recommend working closely with each vendor to match these mea-

The SD-OCT procedures outlined below are currently being performed

surement diameters around the optic disc. Additionally, the automatic

using the SPECTRALIS HRA + OCT hardware and the Eye Explorer

segmentation results may be validated by periodic batches of manual

(HEYEX) version 1.10.4.0 (Heidelberg Engineering, Heidelberg,

segmentation.

Germany) software with structural, angiographic, autofluorescence,
and widefield imaging capabilities. For centers using a Heidelberg
SPECTRALIS, the targeted signal quality value of the structural and

1.4.2

Outcome variables and analysis

angiographic images should be at least 20 for the purpose of quality
control for image analysis, and an automatic real time (ART) value of at

pRNFL thickness is the variable of interest with respect to optic disc

least 7. Prior to imaging, wherever possible, all participants should be

imaging, due to the evidence in the literature indicating changes to

dilated with two drops of tropicamide (Mydriacil 1%) per eye. There is

the pRNFL in AD.13,14 Outcome variables include the average pRNFL

a 15-minute wait time from drop instillation to image acquisition. We

thickness (in microns) in the seven standard glaucoma fields centered

recommend completing all imaging procedures for both the right and

on the optic disc (global average [G], temporal [T, 315-45˚], temporal

the left eye. Doing so allows for the inclusion of research participants

superior [TS, 45-90˚], temporal inferior [TI, 90-135˚], nasal [N, 135-

who have pathology in a single eye, and provides a margin of error if

225˚], nasal superior [NS, 225-270˚], and nasal inferior [270-315˚]) in

the image quality is less than optimal for a single eye.

each of the three concentric circles. In addition, a progression model to

A common approach in retinal imaging research is to rely on a

assess the longitudinal change in the global pRNFL thickness in each of

random assignment for each subject enrolled in a given study, to

the three concentric circles (3.5, 4.1, and 4.7 mm) is completed for each

choose either the right eye (oculus dexter, OD) or left eye (oculus sinister,

participant. Notably, these fields may differ slightly among commercial

OS) for data analyses. In practice, the decision to use data from OD

vendors.

versus OS is dependent on the image quality for each eye, participant
cooperation during the scanning process, and the presence or absence
of ocular pathologies (in each eye) that might adversely impact the

1.4.3

Structural SD-OCT imaging at the macula

quality of the SD-OCT measurements. In Table 1, we provide a listing of
ocular and retinal pathologies that, if of sufficient severity so as to limit

Our standard protocol uses the preset posterior-pole imaging mod-

the quality of imaging data, would result in choosing one eye over the

ule on the SPECTRALIS, with fixation on the fovea. This protocol
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TA B L E 1 List of ocular pathologies that influences choice of either eye or exclusion of participants altogether in the event of a bilateral
condition for the purpose of image analysis
Anterior segment conditions

Posterior segment conditions

Dense cataracts (that impede image quality)

Age-related macular degeneration

Corneal disease affecting media visualization or opacity

Diabetic retinopathy

Unusually high myopia/refractive errors (>or <5.0 diopters) native
spherical equivalent, substantial media opacity, or corneal disease
that may provide accurate visualization of the retinal fundus

Hypertensive retinopathy

Anterior uveitis

Other retinal vascular diseases, eg, retinal ischemic changes, central (or
branch) retinal vein occlusion, central (or branch) retinal artery occlusion,
retinal vasculitis
Macular diseases, eg, epiretinal membrane, macular hole, vitreomacular
traction syndrome
High myopic eyes associated with posterior staphyloma
Glaucoma
Optic nerve disease, eg, optic disc edema, inflammatory, ischemic,
compressive, hereditary, toxic, and nutritional optic neuropathies
Cystoid macular edema
Substantial media opacity, eg, floaters, asteroid hyalosis, vitreous hemorrhage
History of retinal or macular surgery in the past 6 months
Posterior uveitis
History of intravitreal injections

computes the thickness of all retinal layers. Recent work shows that
this automated software segmentation has excellent agreement
with trained observers in evaluating retinal layer boundaries and
thicknesses in patients with neurodegenerative disease.15 For quality
control purposes, obvious errors in segmentation lines are manually
corrected in all B scans spanning a 6 mm Early Treatment Diabetic
Retinopathy Study (EDTRS) grid. Examples of obvious errors, following
Wong et al.,15 include errors visible on quick inspection due to image
acquisition errors or pathology. Again, similarly high-quality macular
structural imaging may be obtained from all differing types of current
SD-OCT systems that are in use by research centers around the world.

1.4.4
F I G U R E 1 A composite diagram showing a 30 × 25 degree
spectral domain optical coherence tomography (SD-OCT) grid
centered on the macula with an individual SD-OCT scan through the
fovea (61 B-scans, 123 microns between B-scans; A, a segmented
foveal B-scan, with retinal neuronal layers delineated [B], and a 3D
representation of the foveal B-scan in space [C]). T, N, I, represent the
temporal, nasal, and inferior portions of the retina respectively. Figure
by Dr. E Arthur

Outcome variables and analysis

Most software to support the OCT systems offered by any major
vendor, including Heidelberg’s HEYEX software, will automatically
compute retinal layer thicknesses (in microns) of the mRNFL, GCL, IPL,
INL, OPL, ONL, IS and OS, and the RPE. The retinal layer segmentation
algorithm of the HEYEX software has been validated against manual
segmentation previously in neurodegenerative disease.15 Volume
measurements (in mm3 ) of all the above-mentioned retinal layers
may also be computed. An ETDRS map consisting of three concentric
circles of diameters 1, 3, and 6 mm centered on the macula is produced

encompasses a macular centered SD-OCT grid of size 30˚× 25˚ (∼8.8

automatically by the HEYEX software (ETDRS, 1991). The ETDRS map

× 7.4 mm) with 61 B-scans across the macula, 123 microns spacing

is a pseudo-color thickness map providing average retinal thickness

between B-scans, and 10 frames averaged per each B-scan location

and volume measurements of the above-mentioned retinal layers

(see Figure 1). The HEYEX software automatically segments and

for the fovea, inner, and outer retinal regions corresponding to the
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1, 3, and 6 mm diameter circles, respectively, centered on the fovea.

imaging.23 In symptomatic AD patients, fundus autofluorescence with

Inner and outer retinal layer thicknesses are considered because

SLO has been used to quantify retinal amyloid in vivo, and confirmed

these layers have been indicated to remodel with AD.16–20 The inner

by autopsy.24–26

and outer regions are both divided into the superior, inferior, nasal,
and temporal portions, which, when combined with the foveal region
adds up to a retinal thickness map of nine regions (ETDRS, 1991).

1.7

Outcome variables and analysis

The accurate centering of the ETDRS map on the fovea of all study
participants is verified by the retinal photographer to ensure accurate

We use the Heidelberg Explorer (HE) region finder tool of the HEYEX

retinal thickness values of the retinal layers for all nine regions.

software to compute the number count and total surface area of

In addition to analysis of the ETDRS grid, we analyze an 8 × 8 mm

the inclusion bodies in the autofluorescence images. This tool allows

posterior pole grid centered on the macula. We use Heidelberg’s

the operator to place a seed in an area of interest, and the software

HEYEX software with NSite Analytics© to compute the retinal thick-

automatically computes the boundary of the object. On visual inspec-

ness values of all of the retinal layers for the 64 boxes within the 8 ×

tion, the rater has the ability to modify the boundaries as required.

8 mm posterior pole grid. This provides a more localized analysis of reti-

All images are read by two qualified and independent raters, and

nal layer thickness across the macula, rather than relying on average

we exclude the 360-degree region within 1 disc diameter from the

volume and thickness. Software analytics packages designed to work

center of the optic disc and the 360-degree macular region within

with imaging systems from other manufacturers will provide very sim-

1 disc diameter of the foveal center. This is done to avoid including

ilar metrics.

the area of hypopigmentation around the optic nerve in participants
with zone α or β crescents or peripapillary atrophy and to avoid
inclusion of age-related macular drusen in these two regions. Inclusion

1.5

Additional imaging modalities

bodies are only counted if they reach 100% consensus ratings in two
independent raters, who are blind to participant information, including

While research on structural retinal biomarkers in AD is furthest along

demographics, medical history, and clinical status.

in terms of discovery work, there is an expanding body of literature
elucidating changes in retinal proteinopathies and the retinal vasculature in AD, with the hopes of creating sensitive and specific biomarkers to detect AD risk and monitor disease progression. At this point,
it is unknown which retinal biomarker, or combination thereof, will be

2
RETINAL ANGIOGRAPHIC CHANGES:
OPTICAL COHERENCE TOMOGRAPHY
ANGIOGRAPHY (OCT-A) IMAGING

useful at each stage of the neurodegenerative continuum. Here, we
list imaging acquisition and analysis procedures for the ARIAS trial to

We collect a macular centered 20˚× 20˚ (6 × 6 mm) OCTA image con-

examine retinal Aβ and retinal vascular changes in cognitively normal

sisting of 512 B-scans, with 12 micron spacing between B-scans, and

older adults, mild cognitive impairment (MCI) patients, and mild AD

five frames averaged per each B-scan location for each participant. This

patients.

produces the superficial vascular complex (SVC) angiogram, defined
as the composite retinal vascular plexus from the inner limiting membrane to the IPL using HEYEX software. Although not exactly the same,

1.6
Retinal amyloid beta (Aβ): autofluorescence
imaging

similar scan parameters are available on other commercial platforms as
shown in Table 2.

Autofluorescence imaging is available within the Heidelberg SPECTRALIS system to examine the presence of Aβ in the retinal neuronal

2.1

Outcome variables and analysis

layers. We use a 55˚ widefield lens to acquire fundus autofluorescence
(FAF) images of the central, superior, and inferior retina of all study

The outcome variables measured from the OCT-A images include

participants using SPECTRALIS confocal scanning laser ophthalo-

foveal avascular zone (FAZ) size, capillary density, capillary non-

moscopy (cSLO). The wider lens is used to capture a larger surface area

perfusion area, and multifractal properties as measured by the gener-

and to search for putative evidence of amyloidosis in the periphery.

alized dimension and singularity spectra. All of these metrics appear to

If this lens is not available, use of the standard lens is appropriate for

be influenced by the presence of AD.27–29

this data, as long as the lens and field of view are specified at the time

At the present time, there is little broad agreement on how best

of dissemination of results. The composite image is then evaluated

to process the highly complex OCT-A imaging data that can now be

for number and surface area of inclusion bodies suspected to contain

easily acquired, as processing technology is still relatively new. There

amyloid proteins.21,22 Retinal inclusion bodies have been previously

is a rapidly growing number of published methods for OCT-A signal

found in the retina of preclinical AD research participants, with the

analyses and data reporting, and currently little agreement on stan-

number and surface area of these inclusion bodies being moderately

dard metrics. MarkVCID represents an ongoing multicenter initiative

correlated with a standard index of amyloid aggregation on PET brain

to develop consensus methodology for OCTA in the assessment of

TABS
Segmentation

cSLO, blue light
autofluorescence
OCT-A

OCT-A

6 × 6 mm or 7 × 7 mm
SD-OCT grid centered on
the macula
55◦a

20◦ ×◦ 20◦ (6 × 6 mm)
SD-OCT grid centered on
the macular

3 × 3 mm or 6 × 6mm
SD-OCT grid centered on
the macula

256
(128)

NA

512

128

Widefield autofluorescence
imaging
(8 to 10 minutes for OS and OD)

Optical Coherence Tomography
Angiography imaging at the
macula
(8 to 10 minutes for OS and OD)

43

Macular Cube
Scan 512 × 128

6 × 6mm SD-OCT grid
centered on the macula

FAZ size, capillary density,
capillary nonperfusion,
multifractal dimension

Surface area and volume of
inclusion bodies

Full retinal thickness in the
nine field ETDRS map, and
ganglion cell thicknesses in
the macula six grid

FAZ size, capillary density,
Zeiss Cirrus Angioplex
capillary nonperfusion,
Software, custom software
fractal dimension
(Matlab, Mathworks), and
ImageJ

Heidelberg Eye Explorer,
custom programming
software (MatLab,
Mathworks), Image
processing software
(Image J)

Heidelberg Eye Explorer, HE
Region Finder

Topcon Fastmap and
IMAGEnet 6 Software

Zeiss Cirrus Macular Analysis All individual retinal layerc
Software
thicknesses and volumes in
the nine field ETDRS map

All individual retinal layerc
thicknesses and volume in
the nine field ETDRS map

128

Heidelberg Eye Explorer,
glaucoma module

HRA+OCT

30◦ ×◦ 25◦ (∼8.8 × 7.4 mm)
SD-OCT grid centered on
the macular

61

Structural SD-OCT imaging at
the macula
(2 to 5 minutes for OS and OD)

pRNFL thickness in the
clockhour, quadrant, and
overall average glaucoma
standard fields, disc area,
cup-to-disc ratio

TABS
Topcon Fastmap and
Segmentation43
IMAGEnet 6 Software

3.4 mm diameter annulus
centered on the optic disc
6 × 6 mm

256
(128)

Outcome
variables

Heidelberg Eye Explorer with pRNFL thickness in the seven
N-Site Analytics
glaucoma standard fields

Processing
software

pRNFL thickness, disc area,
cup-to-disc ratio

Optic Disc Cube
200 × 200

3.4 mm diameter concentric
circle centered on the
optic disc
6 × 6mm

200

Image analysis
technique

HRA + OCT
3.5, 4.1, and, 4.7 mm
diameter concentric circles
centered on the optic disc

Size of field

27

Number
of
B-scans

Zeiss Cirrus Optic Nerve
Analysis Software

Structural SD-OCT imaging at
Proposed
optic disc (2 to 5 minutes for
“Minimum
OS and OD)
Data Set”

Retinal imaging
modality

(Continues)

Enlarged FAZ, reduced vessel
branching, tortuosity,
density, reduced blood
flow

Aβ aggregation, tau
aggregation, associated
with cerebral Aβ, tau

mRNFL thinning, GC-IPL
thinning, structural
changes associated with
cerebral biomarker and
cognitive changes

pRNFL thinning

Reported findings
in ADb

TA B L E 2 Summary of the retinal imaging modalities, techniques of retinal image analysis, and outcome variables, using Heidelberg SPECTRALIS and Zeiss equipment. Specifications provided for
each manufacturer are exemplars; there are additional manufacturers of quality SD-OCT equipment that are not listed. For individual system specifications, for each manufacturer, see Schott42
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Retinal imaging
modality

FAZ measures (area,
perimeter, circularity),
macular and RPC vessel
densities
Topcon Fastmap and
IMAGEnet 6 Software
OCT-A
3 × 3 mm, 4.5 × 4.5 mm, 6 × 6
mm, 9 × 9 mm, 12 × 12 mm
SS-OCT scan area
centered on the macula or
disc
320 or
512

Abbreviations: Aβ, amyloid beta; AD, Alzheimer’s disease; cSLO, confocal scanning laser ophthalomoscopy; ETDRS: Early Treatment Diabetic Retinopathy Study; FAZ, foveal avascular zone; ; NA, not applicable;
OD, oculus dexter; OS, oculus sinister; pRNFL, peripapillary retinal nerve fiber layer; RPC, radial peripapillary capillary; SD-OCT, spectral domain optical coherence tomography; SS-OCT, swept source optical
coherence tomograph.
a
Widefield (55 deg) lens should be used if available.
b
See Alber et al.2 for review.
c
Retinal layers include macular retinal nerve fiber layer (mRNFL), ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL), inner and
outer photoreceptor segments (IS and OS), and the retinal pigment epithelium (RPE).

TA B L E 2

(Continued)

Number
of
B-scans

Size of field

Image analysis
technique

Processing
software

Outcome
variables

Reported findings
in ADb
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vascular cognitive impairment or dementia. The methodology of this
study will soon be available and will likely aid in the harmonization
of angiography data. Below, we offer one approach that our group is
focusing on, as these methods may be reproduced with relative ease
using widely available software, as described below.
The HEYEX software lasso tool is used to delineate the borders of
the FAZ, to allow for surface area measurement on the SVC image.
After this, we export the SVC images as tiff files into custom programming software (Matlab, Mathworks) for further image processing and analysis. First, a vesselness filter is applied to the images30,31
to increase the probability of resolving a vessel at a specific location
in the image when it is actually present versus noise or motion artifact. Next, the Otsu thresholding method32 is applied to the resultant
image to reduce background noise. After the thresholding, we use a
customized program script33 to count the number of pixels designated
as vessels. These thresholding and pixel counting methods are applicable to all OCTA images, regardless of device used for acquisition. The
number of pixels is then converted into mm2 based on the micron-topixel ratio in the x and y directions, as computed from the fiducial marks
acquired from the HEYEX software. The resultant value in mm2 is the
capillary density in the SVC. To compute the area of non-perfusion, we
subtract the computed capillary density from the known area of the
SVC angiogram (36 mm2 ).
To investigate the fractal properties of the retinal vascular network
in the processed SVC angiogram, all images are analyzed using the
image processing software Image J (Wayne Rasband, National Institutes of Health in Bethesda, Maryland, USA) together with the FracLac
plugin (A. Karperien—Charles Sturt University, Australia). We compute
the multifractal properties of the retinal vascular plexus in the SVC
using the generalized dimension and singularity spectra.28,29,34,35 Several other analysis platforms are available either from other commercial vendors or research groups specializing in angiography analysis.36
Table 2 summarizes the retinal imaging modalities of this framework, techniques for retinal image analysis, and outcome variables for
our suggested methodological framework.

3

SUMMARY AND DISCUSSION

Here, we suggest a reproducible methodology to serve as a recommended “minimum data set” for collection and analysis of retinal
images in AD research, in hopes of harmonizing data to generate rapid
discovery and moving the field toward validating sensitive and specific
retinal biomarkers for AD risk and to monitor disease progression. This
recommended protocol is offered as a starting point to address one of
the key needs identified by experts from academia, industry, federal
agencies, and regulatory authorities at the May 2019 Retinal Imaging in
Alzheimer’s Disease Summit, organized by the Alzheimer’s Association.
Our primary focus for the recommended minimum data set is structural retinal changes, measured via retinal neuronal layer thickness
and volume and assessed with SD-OCT. This has been extensively
reviewed in the literature,2,37 using common imaging procedures
and techniques in clinical optometry and ophthalmology practice.
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We added additional methodology and outcome measures for the

The field will need to address additional methodological barriers

assessment of retinal amyloid, and retinal angiography. Although

to produce validated, clinically meaningful and applicable biomarkers.

these latter imaging approaches currently require more specialized

Both AD and cancer have seen success in public–private partnerships,

equipment that is less widely available, several laboratories are cur-

which can be leveraged for the advancement of retinal biomarker val-

rently exploring both protein-related and angiographic retinal changes

idation in AD. As one example, O’Bryant et al.41 proposed a pathway

across the AD spectrum. The techniques used by laboratories in these

for the advancement of plasma biomarkers from discovery to clinic,

areas vary, sometimes considerably, across laboratory groups. Our

including public–private partnerships, which could be applied to reti-

hope is this recommended minimum data set represent a first step

nal biomarkers in the future. Finally, we expect future retinal biomarker

toward galvanizing researchers to align protocols for retinal imaging

discovery work in academia to modify our recommendations for a min-

biomarker research in AD.

imum data set framework as the pace and popularity of this work in

To generate this recommended minimum data set, we began with

AD increases. This framework is not meant to be exhaustive, but rather

a protocol developed in consultation with industrial and academic

a starting point from which to move forward as a field. For exam-

experts for and currently used in the ARIAS study (PIs: Snyder, Sinoff).

ple, methodological factors, such as lighting,39,40 may influence reti-

We consulted with national and international experts to expand upon

nal morphology. As such, standardization of lighting conditions may

and modify this protocol, resulting in the above recommended mini-

require standardization in the future, although whether this makes a

mum data set for retinal imaging biomarker discovery research in AD.

significant difference in AD measurements remains to be systemati-

Our goal is to increase methodological concordance across laborato-

cally investigated.

ries, so that the broader research community is able to cross-validate

Looking to the future, use of this minimum data set could spur

findings in parallel, accumulate large databases with normative data

efficient data accumulation and analysis in the field, including data

across the cognitive aging spectrum, and progress from the discovery

examining within subjects, longitudinal change in cognitive aging, and

stage to the validation stage in terms of retinal biomarker development

AD. These data are essential to move from discovery to validation, and

for AD.

to examine which retinal AD biomarkers may be sensitive and specific

Although we believe this framework makes a start at filling an

for the different stages of the cognitive aging continuum. This approach

unmet need in the field, we understand that this is a first step in

has been successful in validating other biomarkers for AD, such as MRI,

working toward reliable methodological harmonization across lab-

amyloid PET, and blood proteomics. Moreover, designating an appro-

oratories, and that many additional steps must be taken to achieve

priate context of use for structural, protein-related, and microvascular

true methodological concordance across labs in academia, the clinic,

retinal biomarkers will be essential to move the field forward. There

and in industry. We acknowledge that this minimum data set will not

are many potential contexts of use for these biomarkers, including, but

necessarily be applicable across all devices and manufacturers, and

not limited to, point-of-care screening, risk for pre-clinical AD or risk of

that solving technological and technical variations, even subtle ones

progression from MCI to AD, monitoring, diagnosis, or prognosis. Clin-

due to software variations in the same device, will require co-operation

ical applicability of these biomarkers will depend on context of use; for

and data-sharing across federal and regulatory agencies, experts in

example, structural retinal biomarkers have been studied extensively

academia and industry, and device manufacturers. Some of the soft-

in AD patients versus age-matched cognitively normal older adults;

ware described in this minimum data set is not part of the “standard”

however, investigations of these biomarkers in the preclinical AD

Heidelberg software package (NSite Analytics, OCT-A, Widefield

population remains limited. It is essential to determine at which stage

Imaging Module, HE Region Finder tool, see Table 2), and acquisition of

of the cognitive aging continuum these retinal biomarkers are most

this software incurs additional costs, which may not be feasible for all

reliable and accurate, and how they would most efficiently be deployed

research laboratories. One potential strategy to expedite data sharing

in clinical practice. In the future, retinal imaging could be deployed

is providing access to real raw image data, without any post-processing.

as a tool for large-scale screening of cognitively normal older adults.

Although this would require cooperation of device manufacturers,

As a field, our goals should center on precision medicine approaches

working with these data would be helpful in terms of expediting

for AD diagnosis and monitoring by minimizing clinician burden;

collaborative efforts and cross-validation in the field. To that end,

maximizing clinical utility; and identifying individuals at risk for AD for

there are free image reading platforms available that often produce

further specialist evaluation and more invasive, expensive biomarker

comparable results to the vendor software, including Ometto et al.’s

testing. Retinal biomarkers could play a pivotal role in large-scale

ReLayer38

software and the National Institutes of Health’s Image J

screening, and serve as a first step in a multi-stage biomarker testing

software. SD-OCT images on the SPECTRALIS can be exported as

process, similar to other disease states such as cancer, cardiovascular

.tiff files instead of HEYEX software’s standard .E2E files. The .tiff file

disease, and diabetes. It is important to note that to truly validate

formats can be viewed by any non-proprietary image software, such as

retinal imaging as an AD screening tool, we will have to develop

Image J, to decouple reliance on proprietary software and pre-/post-

biomarkers that are specific to AD pathology. As health co-morbidities,

processing. These platforms will help to advance the field toward

specifically cardiovascular disease and diabetes, increase with age, it

sharing raw, unprocessed SD-OCT data and retinal images, especially

is not uncommon for older adults to present with multiple pathologies

in cases in which vendor specific software is not available or not

that affect the retina. However, aiming for a screening tool with high

affordable.

negative predictive value that can rule out low-risk older adults,
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will be a valuable first screening stage. Retinal biomarkers have the
potential to limit use of invasive and costly tests, such as brain imaging
and cerebrospinal fluid sampling, and will help to precisely identify
those at high risk for AD when a disease-modifying therapy becomes
available.
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